1. Rosamond W et al. Heart Disease and Stroke Statistics – 2008 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25–e146.
2. Young AR, Ali C, Duretete A, Vivien D. Neuroprotection and stroke: time for a compromise. J Neurochem 2007; 103: 1302–9.
3. Гусев Е.И., Скворцова Л.В., Стаховская Л.В., Киликовский В.В., Айриян Н.Ю. Эпидемиология инсульта в России. Consilium Medicum. Неврология. 2003; спец. выпуск: 5–7.
4. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001.
5. Adams HP, del Zoppo G, Alberts MJ et al. Guidelines for the Early Management of Adults With Ischemic Stroke. A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke 2007; 38: 1655–711.
6. Roach ES, Golomb MR, Adams R et al. Management of Stroke in Infants and Children. A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39.
7. van der Worp HB, Sena ES, Donnan GA et al. Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain 2007; 130 (12): 3063–74.
8. Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies – the need for new approaches. Cerebrovasc Dis 2004; 17 (Suppl. 1): 153–66.
9. Donnan GA. A New Road Map for Neuroprotection. The 2007 Feinberg Lecture. Stroke 2008; 39: 242.
10. Chacon MR, Jensen MB, Sattin JA, Zivin JA. Neuroprotection in cerebral ischemia: emphasis on the SAINT trial. Curr Cardiol Rep 2008; 10 (1): 37–42.
11. Olesen J, Baker MG, Freund T et al. Consensus document on European brain research. J Neurol Neurosurg Psychiat 2006; 77; i1–i49.
12. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008. [Epub ahead of print] 11. Bacigaluppi M, Hermann DM. New targets of neuroprotection in ischemic stroke. Scientific World J 2008; 13 (8): 698–712.
13. Gutierrez M, Tejedor ED, de Lecinana MA et al. Thrombolysis and neuroprotection in cerebral ischemia. Cerebrovasc Dis 2006; 21 (Suppl. 2): 118–26.
14. Lees KR. Management of acute stroke. Lancet Neurology 2002; 1: 41–50.
15. Ovbiagele B, Kidwell CS, Starkman S, Saver JL. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2003; 3 (1): 9–20.
16. Ly JV, Zavala JA, Donnan GA. Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke. Expert Opin Pharmacother 2006; 7 (12): 1571–81.
17. Fu Y, Sun JL, Ma JF et al. The neuroprotection of prodromal transient ischaemic attack on cerebral infarction. Eur J Neurol 2008.
[Epub ahead of print] 
18. Steiger HJ, Hanggi D. Ischaemic preconditioning of the brain, mechanisms and applications. Acta Neurochir (Wien) 2007; 149 (1): 1–10.
19. Green AR. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. Br J Pharmacol 2008; 153 (Suppl. 1): S325–38.
20. Yenari M, Kitagawa K, Lyden P, Perez-Pinzon M. Metabolic Downregulation. A Key to Successful Neuroprotection? Stroke 2008.
21. Alonso de Lecinana M, Gutierrez M, Roda JM et al. Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke. J Neurol Sci 2006; 247: 121–9.
22. Alvarez XA, Laredo M, Corzo D et al. Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol 1997; 19: 201–10.
23. Aronowski J, Strong R, Grotta JC. Citicoline for treatment of experimental focal ischemia: histologic and behavioral outcome. Neurol Res 1996; 18: 570–4.
24. Clark WM, Warach SJ, Pettigrew LC et al. A randomized dose–response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 1997; 49: 671–8.
25. Clark WM, Williams BJ, Selzer KA et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999; 30: 2592–7.
26. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE; Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001; 57: 1595–602.
27. Petkov VD, Kehayov RA, Mosharrof AH et al. Effects of cytidine diphosphate choline on rats with memory deficits. Arzneimittelforschung 1993; 43: 822–8.
28. Schabitz WR, Weber J, Takano K et al. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. J Neurol Sci 1996; 138: 21–5.
29. Secades JJ, Alvarez-Sabin J, Rubio F et al. Citicoline in intracerebral haemorrhage: a double–blind, randomized, placebo-controlled, multi–centre pilot study. Cerebrovasc Dis 2006; 21: 380–5.
30. Shuaib A, Yang Y, Li Q. Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase. Exp Neurol 2000; 161: 733–9.
31. Tazaki Y, Sakai F, Otomo E et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double–blind placebo–controlled study. Stroke 1988; 19: 211–6.
32. Нордвик Б. Механизм действия и клиническое применение препарата актовегин. В сб.: Актовегин. Новые аспекты клинического применения. М., 2002; 18–24.
33. Румянцева С.А. Фармакологические характеристики и механизм действия актовегина. В сб.: Актовегин. Новые аспекты клинического применения. М., 2002; 3–9.
34. Федин А.И., Румянцева С.А. Антиоксидантная терапия нарушений мозгового кровообращения. Актовегин в неврологии. Под ред. С.А.Румянцевой. Сборник научно-практических статей. М., 2002; 74–84.
35. Румянцева С.А., Беневоленская Н.Г., Евсеев В.Н. Антигипоксанты в реаниматологии и неврологии. Рус. мед. журн. 2004; 22: 302–4.
36. Янсен В., Брукнер Г.В. Лечение хронической цереброваскулярной недостаточности с использованием драже Актовегин форте (двойное слепое плацебо-контролируемое исследование). Рус. мед. журн. 2002; 12–13: 543–6.
37. Jansen W, Beck E. Лечение диабетической полинейропатии. Контролируемое двойное слепое исследование. В сб.: Опыт клинического применения актовегина в эндокринологии. М., 2005; 11–20.
38. Kinzler E, Lehmann E, Groth J et al. Actovegin in der Behandlung geriatrischer Patienten mit hirnorganischem psychosyndrom. Munch Med Wochenschr 1988; 130; 644–6.
39. Oswald WD, Steger W, Oswald B et al. Die Verbesserung fluider kognitiver Leistungen als Indikator fur die klinische Wirksamkeit einer nootropen Substanz.Eine placebokontrollierte Doppelblind-Studie mit Actovegin. Z Gerontopsychol Psychiat 1991; 4: 209–20.
40. Saletu B, Grunberger J, Linzmayer L et al. EEG brain mapping and psychometry in age–associated memory impairment after acute and 2–week infusions with the hemoderivative Actovegin: double–blind, placebo–controlled trials. Neurophychobiol 1990/1991; 24: 135–48.
41. Semlitsch HV, Anderer P, Saletu B et al. Topographic mapping of cognitive event–related potentials in a double–blind, placebo–controlled study with the hemoderivative Actovegin in age–associated memory impairment. Neurophychobiol 1990/1991; 24: 49–56.
42. Obermaier-Kuser B, Muchibacher Ch, Mushack J et al. Further evidence for a fwo-step model of glucose transport regulation. Biochem J 1989; 261: 699–705.

М.В.Путилина